3 Japanese AI Healthcare Stocks Trading Below Fair Value

With inflation, supply chains and interest rates all pulling markets in different directions, some investors are looking for themes that do not rely solely on broad economic strength. Transformative AI healthcare stocks sit at that intersection, where powerful data tools meet essential services that people depend on regardless of the cycle. This screener focuses on companies using AI to improve diagnostics, treatment decisions and efficiency, a trend supported by growing pressure to control costs and expand access to care. In this article, you will see 3 of the strongest examples from the Transformative AI Healthcare Stocks screener.

Overview: ASO International is a Japan based specialist in dental orthodontics, offering a wide range of AI supported digital tools, 3D printers and customized orthodontic devices such as aligners, lingual systems and retainers for clinics and patients.

Market Cap: ¥6.8b

ASO International stands out in AI enabled healthcare because it brings together orthodontic expertise with digital tools like WE SCAN, an AI assisted correction system, and a suite of 3D printers and services that can make treatment planning more precise and efficient. The stock is trading 32.8% below one estimate of fair value, and analysts expect revenue and earnings to grow at steady double digit rates, which may appeal to investors who value consistency. High quality earnings and a current net margin of 12.3% suggest the business is profitable, yet there are important flags, including zero independent directors and heavy reliance on external borrowing. For investors who can balance those risks, the mix of AI, recurring clinical demand and apparently modest valuation could be worth a closer look.

ASO International’s mix of AI driven orthodontics, recurring clinical demand and a stock price sitting 32.8% below one estimate of fair value raises an obvious question. See the DCF valuation analysis for ASO International and how the funding structure could change the picture.

Overview: eWeLLLtd runs a cloud platform for home based medical care in Japan, offering electronic medical records, insurance claim systems, staffing tools, AI supported nursing reports, e learning and factoring services that help visiting nursing stations handle both clinical work and back office administration in one place.

Market Cap: ¥28.3b

eWeLLLtd draws attention in AI healthcare because it sits at the heart of home nursing workflows, combining AI assisted reporting with tools that handle medical records, claims and staff management for a growing part of Japan’s care system. Earnings and revenue are both expected to grow at around 20% a year with ROE above 30%, and the stock trades below one estimate of future cash flow value, which may interest growth focused investors. At the same time, the P/E sits above sector averages and the company relies entirely on higher risk external funding, while board independence is limited. Those trade offs, together with recent buybacks and higher dividend guidance, make eWeLLLtd a stock where the full risk reward picture really matters before taking a view.

Rapid 20% growth expectations, high ROE and a stock below one estimate of future cash flow value make eWeLLLtd hard to ignore. Get the full story from the analyst forecasts for eWeLLLtd and learn why the funding choices might be the twist investors are missing.

Overview: FINDEX is a Japan based healthtech company that builds software and devices for hospitals and clinics, from electronic medical records and image filing systems to AI tools like CocktailAI for medical text generation and DigiWorker for automating routine healthcare admin.

Market Cap: ¥19.3b

FINDEX brings together hospital software, medical data tools and generative AI at a scale that is starting to show up clearly in its financials, with 5 year earnings growth of 22.4% a year, a 20.2% net margin and a 22.3% return on equity (ROE. The stock trades on a price to earnings (P/E) ratio below the Asian healthcare services average and 39.4% under one estimate of fair value. Management is guiding to continued profit and dividend stability into 2026. Against that, funding relies entirely on higher risk external borrowing and board independence is limited, so the quality of cash flows and the board’s capital allocation decisions are important factors for investors to monitor.

FINDEX combines hospital software, strong margins and a P/E below the Asian healthcare services average, which may mean investors are missing something. See the analysis report for FINDEX to understand why that discount might not tell the full story.

The three stocks in this article are only a starting point, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaced four more companies with equally compelling AI healthcare stories that you have not seen yet. Use Simply Wall St to identify the specific catalysts and narratives that matter most to you, and analyze this group so you can focus on the highest conviction opportunities in the sector.

Take Control of Your Investment Journey

If ASO International or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Curious About What You Might Be Missing?

Fresh stock ideas can move from quiet buildup to full breakout quickly. Once the crowd catches on, the edge starts dropping away, so getting in early can matter.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com